Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 2/2013

01.04.2013

Parathyroid Hormone, A Crucial Mediator of Pathologic Cardiac Remodeling in Aldosteronism

verfasst von: Michael R. Rutledge, Victor Farah, Adedayo A. Adeboye, Michael R. Seawell, Syamal K. Bhattacharya, Karl T. Weber

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Aldosteronism, or chronic elevation in plasma aldosterone (ALDO) (inappropriate for dietary Na+ intake), is accompanied by an adverse structural remodeling of the heart and vasculature. Herein, we bring forward a new perspective in which parathyroid hormone (PTH) is identified as a crucial mediator of pathologic cardiac remodeling in aldosteronism. Secondary hyperparathyroidism (SHPT) appears because of the marked urinary and fecal losses of Ca2+ and Mg2+ that accompany aldosteronism which creates ionized hypocalcemia and hypomagnesemia, providing major stimuli to the parathyroids' enhanced secretion of PTH. Invoked to restore extracellular Ca2+ and Mg2+ homeostasis, elevations in plasma PTH lead to paradoxical intracellular Ca2+ overloading of diverse tissues. In the case of cardiomyocytes, the excessive intracellular Ca2+ accumulation involves both cytosolic free and mitochondrial domains with a consequent induction of oxidative stress by these organelles and lost ATP synthesis. The ensuing opening of their inner membrane permeability transition pore (mPTP) accounts for the osmotic swelling and structural degeneration of mitochondria followed by programed cell necrosis. Tissue repair, invoked to preserve the structural integrity of myocardium accounts for a replacement fibrosis, or scarring, which is found scattered throughout the right and left heart; it represents a morphologic footprint of earlier necrosis. Multiple lines of evidence are reviewed that substantiate the PTH-mediated paradigm and the mitochondriocentric signal-transducer-effector pathway to cardiomyocyte necrosis.
Literatur
1.
2.
Zurück zum Zitat Funder JW, Reincke M. Aldosterone: a cardiovascular risk factor? Biochim Biophys Acta. 2010;1802:1188–92.PubMedCrossRef Funder JW, Reincke M. Aldosterone: a cardiovascular risk factor? Biochim Biophys Acta. 2010;1802:1188–92.PubMedCrossRef
3.
Zurück zum Zitat FritschNeves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59–65.CrossRef FritschNeves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59–65.CrossRef
4.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.PubMedCrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.PubMedCrossRef
5.
Zurück zum Zitat Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef
6.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef
7.
Zurück zum Zitat Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43:716–9.PubMedCrossRef Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43:716–9.PubMedCrossRef
8.
Zurück zum Zitat Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–54.PubMed Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–54.PubMed
9.
Zurück zum Zitat Resnick LM, Nicholson JP, Laragh JH. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254–8.PubMedCrossRef Resnick LM, Nicholson JP, Laragh JH. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254–8.PubMedCrossRef
10.
Zurück zum Zitat Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197–207.PubMedCrossRef Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197–207.PubMedCrossRef
11.
Zurück zum Zitat Alsafwah S, LaGuardia SP, Nelson MD, Battin DL, Newman KP, Carbone LD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci. 2008;335:292–7.PubMedCrossRef Alsafwah S, LaGuardia SP, Nelson MD, Battin DL, Newman KP, Carbone LD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci. 2008;335:292–7.PubMedCrossRef
12.
Zurück zum Zitat LaGuardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332:112–8.PubMedCrossRef LaGuardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332:112–8.PubMedCrossRef
13.
Zurück zum Zitat Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884–93.PubMedCrossRef Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884–93.PubMedCrossRef
14.
Zurück zum Zitat Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385–90.PubMedCrossRef Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385–90.PubMedCrossRef
15.
Zurück zum Zitat Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14:219–31.PubMed Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14:219–31.PubMed
16.
Zurück zum Zitat Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912–9.PubMedCrossRef Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912–9.PubMedCrossRef
17.
Zurück zum Zitat Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431–7.PubMedCrossRef Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431–7.PubMedCrossRef
18.
Zurück zum Zitat Rosenberg J, Pines M, Hurwitz S. Stimulation of chick adrenal steroidogenesis by avian parathyroid hormone. J Endocrinol. 1988;116:91–5.PubMedCrossRef Rosenberg J, Pines M, Hurwitz S. Stimulation of chick adrenal steroidogenesis by avian parathyroid hormone. J Endocrinol. 1988;116:91–5.PubMedCrossRef
19.
Zurück zum Zitat Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–6.PubMedCrossRef Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–6.PubMedCrossRef
20.
Zurück zum Zitat Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens. 2008;26:1453–62.PubMedCrossRef Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, et al. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens. 2008;26:1453–62.PubMedCrossRef
21.
Zurück zum Zitat Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358–63.PubMedCrossRef Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358–63.PubMedCrossRef
22.
Zurück zum Zitat Payet MD, Goodfriend TL, Bilodeau L, Mackendale C, Chouinard L, Gallo-Payet N. An oxidized metabolite of linoleic acid increases intracellular calcium in rat adrenal glomerulosa cells. Am J Physiol Endocrinol Metab. 2006;291:E1160–7.PubMedCrossRef Payet MD, Goodfriend TL, Bilodeau L, Mackendale C, Chouinard L, Gallo-Payet N. An oxidized metabolite of linoleic acid increases intracellular calcium in rat adrenal glomerulosa cells. Am J Physiol Endocrinol Metab. 2006;291:E1160–7.PubMedCrossRef
23.
Zurück zum Zitat Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563–75.PubMedCrossRef Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563–75.PubMedCrossRef
24.
Zurück zum Zitat Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002;161:1773–81.PubMedCrossRef Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002;161:1773–81.PubMedCrossRef
25.
Zurück zum Zitat Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871–8.PubMedCrossRef Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871–8.PubMedCrossRef
26.
Zurück zum Zitat Takeda Y. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res. 2009;32:321–4.PubMedCrossRef Takeda Y. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res. 2009;32:321–4.PubMedCrossRef
27.
Zurück zum Zitat Manning Jr RD, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25:311–7.PubMedCrossRef Manning Jr RD, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25:311–7.PubMedCrossRef
28.
Zurück zum Zitat Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67:1355–64.PubMedCrossRef Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67:1355–64.PubMedCrossRef
29.
Zurück zum Zitat Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252:C1–9.PubMed Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252:C1–9.PubMed
30.
Zurück zum Zitat López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645–54.PubMedCrossRef López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645–54.PubMedCrossRef
31.
Zurück zum Zitat Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387–93.PubMedCrossRef Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387–93.PubMedCrossRef
32.
Zurück zum Zitat Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–8.PubMedCrossRef Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–8.PubMedCrossRef
33.
Zurück zum Zitat Díez J. Towards a new paradigm about hypertensive heart disease. Med Clin North Am. 2009;93:637–45.PubMedCrossRef Díez J. Towards a new paradigm about hypertensive heart disease. Med Clin North Am. 2009;93:637–45.PubMedCrossRef
34.
Zurück zum Zitat Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158–64.PubMed Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158–64.PubMed
35.
Zurück zum Zitat Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577–81.PubMedCrossRef Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577–81.PubMedCrossRef
36.
Zurück zum Zitat Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138–47.PubMedCrossRef Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138–47.PubMedCrossRef
37.
38.
Zurück zum Zitat Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578–83.PubMedCrossRef Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578–83.PubMedCrossRef
39.
Zurück zum Zitat Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819–25.PubMedCrossRef Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819–25.PubMedCrossRef
40.
Zurück zum Zitat Sheppard K, Funder JW. Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. Am J Physiol. 1987;252:E224–9.PubMed Sheppard K, Funder JW. Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. Am J Physiol. 1987;252:E224–9.PubMed
41.
Zurück zum Zitat Suki WN, Schwettmann RS, Rector Jr FC, Seldin DW. Effect of chronic mineralocorticoid administration on calcium excretion in the rat. Am J Physiol. 1968;215:71–4.PubMed Suki WN, Schwettmann RS, Rector Jr FC, Seldin DW. Effect of chronic mineralocorticoid administration on calcium excretion in the rat. Am J Physiol. 1968;215:71–4.PubMed
42.
Zurück zum Zitat Massry SG, Coburn JW, Chapman LW, Kleeman CR. The effect of long-term desoxycorticosterone acetate administration on the renal excretion of calcium and magnesium. J Lab Clin Med. 1968;71:212–9. Massry SG, Coburn JW, Chapman LW, Kleeman CR. The effect of long-term desoxycorticosterone acetate administration on the renal excretion of calcium and magnesium. J Lab Clin Med. 1968;71:212–9.
43.
Zurück zum Zitat Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol. 1986;251:F879–88.PubMed Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol. 1986;251:F879–88.PubMed
44.
Zurück zum Zitat Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron. 1988;48:280–3.PubMedCrossRef Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron. 1988;48:280–3.PubMedCrossRef
45.
Zurück zum Zitat Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid “escape” in man. Kidney Int. 1972;2:279–86.PubMedCrossRef Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid “escape” in man. Kidney Int. 1972;2:279–86.PubMedCrossRef
46.
Zurück zum Zitat Zikos D, Langman C, Gafter U, Delahaye B, Lau K. Chronic DOCA treatment increases Ca absorption: role of hypercalciuria and vitamin D. Am J Physiol. 1986;251:E279–84.PubMed Zikos D, Langman C, Gafter U, Delahaye B, Lau K. Chronic DOCA treatment increases Ca absorption: role of hypercalciuria and vitamin D. Am J Physiol. 1986;251:E279–84.PubMed
47.
Zurück zum Zitat Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens. 1998;11:8–13.PubMedCrossRef Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens. 1998;11:8–13.PubMedCrossRef
48.
Zurück zum Zitat Berthelot A, Pernot F, Gairard A. Influence of the thyroid and parathyroid glands on magnesium metabolism during mineralocorticoid treatment (DOCA+NaCl) in the rat. Ann Nutr Metab. 1983;27:349–54.PubMedCrossRef Berthelot A, Pernot F, Gairard A. Influence of the thyroid and parathyroid glands on magnesium metabolism during mineralocorticoid treatment (DOCA+NaCl) in the rat. Ann Nutr Metab. 1983;27:349–54.PubMedCrossRef
49.
Zurück zum Zitat Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187–92.PubMedCrossRef Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187–92.PubMedCrossRef
50.
Zurück zum Zitat Zou AP, Cowley Jr AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1:178–86.PubMedCrossRef Zou AP, Cowley Jr AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1:178–86.PubMedCrossRef
51.
Zurück zum Zitat Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197–202.PubMed Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197–202.PubMed
52.
Zurück zum Zitat Rondón LJ, Groenestege WM, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol. 2008;294:R2001–7.PubMedCrossRef Rondón LJ, Groenestege WM, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol. 2008;294:R2001–7.PubMedCrossRef
53.
Zurück zum Zitat Morrissey JJ, Cohn DV. The effects of calcium and magnesium on the secretion of parathormone and parathyroid secretory protein by isolated porcine parathyroid cells. Endocrinology. 1978;103:2081–90.PubMedCrossRef Morrissey JJ, Cohn DV. The effects of calcium and magnesium on the secretion of parathormone and parathyroid secretory protein by isolated porcine parathyroid cells. Endocrinology. 1978;103:2081–90.PubMedCrossRef
54.
Zurück zum Zitat Mayer GP, Hurst JG. Comparison of the effects of calcium and magnesium on parathyroid hormone secretion rate in calves. Endocrinology. 1978;102:1803–14.PubMedCrossRef Mayer GP, Hurst JG. Comparison of the effects of calcium and magnesium on parathyroid hormone secretion rate in calves. Endocrinology. 1978;102:1803–14.PubMedCrossRef
55.
Zurück zum Zitat DiPette DJ, Greilich PE, Nickols GA, Graham GA, Green A, Cooper CW, et al. Effect of dietary calcium supplementation on blood pressure and calciotropic hormones in mineralocorticoid-salt hypertension. J Hypertens. 1990;8:515–20.PubMedCrossRef DiPette DJ, Greilich PE, Nickols GA, Graham GA, Green A, Cooper CW, et al. Effect of dietary calcium supplementation on blood pressure and calciotropic hormones in mineralocorticoid-salt hypertension. J Hypertens. 1990;8:515–20.PubMedCrossRef
56.
Zurück zum Zitat Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J. 1980;56:45–7.PubMedCrossRef Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J. 1980;56:45–7.PubMedCrossRef
57.
Zurück zum Zitat Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 1980;244:1351–3.PubMedCrossRef Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 1980;244:1351–3.PubMedCrossRef
58.
Zurück zum Zitat Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:1035–41.PubMedCrossRef Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:1035–41.PubMedCrossRef
59.
Zurück zum Zitat Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023–6.PubMedCrossRef Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023–6.PubMedCrossRef
60.
Zurück zum Zitat Palmieri GM, Hawrylko J. Effects of aldosterone on the urinary excretion of total and non-dialyzable hydroxyproline. Horm Metab Res. 1977;9:507–9.CrossRef Palmieri GM, Hawrylko J. Effects of aldosterone on the urinary excretion of total and non-dialyzable hydroxyproline. Horm Metab Res. 1977;9:507–9.CrossRef
61.
Zurück zum Zitat Sellmeyer DE, Schloetter M, Sebastian A. Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab. 2002;87:2008–12.PubMedCrossRef Sellmeyer DE, Schloetter M, Sebastian A. Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab. 2002;87:2008–12.PubMedCrossRef
62.
Zurück zum Zitat Goulding A, Campbell D. Dietary NaCl loads promote calciuria and bone loss in adult oophorectomized rats consuming a low calcium diet. J Nutr. 1983;113:1409–14.PubMed Goulding A, Campbell D. Dietary NaCl loads promote calciuria and bone loss in adult oophorectomized rats consuming a low calcium diet. J Nutr. 1983;113:1409–14.PubMed
63.
Zurück zum Zitat Creedon A, Cashman KD. The effect of high salt and high protein intake on calcium metabolism, bone composition and bone resorption in the rat. Br J Nutr. 2000;84:49–56.PubMed Creedon A, Cashman KD. The effect of high salt and high protein intake on calcium metabolism, bone composition and bone resorption in the rat. Br J Nutr. 2000;84:49–56.PubMed
64.
Zurück zum Zitat Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722–8.PubMedCrossRef Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722–8.PubMedCrossRef
65.
Zurück zum Zitat Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49–55.PubMedCrossRef Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49–55.PubMedCrossRef
66.
Zurück zum Zitat Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504–10.PubMedCrossRef Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504–10.PubMedCrossRef
67.
Zurück zum Zitat Gandhi MS, Deshmukh PA, Kamalov G, Zhao T, Zhao W, Whaley JT, et al. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2008;52:245–52.PubMedCrossRef Gandhi MS, Deshmukh PA, Kamalov G, Zhao T, Zhao W, Whaley JT, et al. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2008;52:245–52.PubMedCrossRef
68.
Zurück zum Zitat Fleckenstein A, Frey M, Fleckenstein-Grun G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J. 1983;4:43–50.PubMedCrossRef Fleckenstein A, Frey M, Fleckenstein-Grun G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J. 1983;4:43–50.PubMedCrossRef
69.
Zurück zum Zitat Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Aldosteronism and a proinflammatory vascular phenotype. Role of Mg2+, Ca2+ and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111:51–7.PubMedCrossRef Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Aldosteronism and a proinflammatory vascular phenotype. Role of Mg2+, Ca2+ and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111:51–7.PubMedCrossRef
70.
Zurück zum Zitat Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 2003;93:e124–35.PubMedCrossRef Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 2003;93:e124–35.PubMedCrossRef
71.
Zurück zum Zitat Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab. 2000;18:109–25.PubMedCrossRef Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab. 2000;18:109–25.PubMedCrossRef
72.
Zurück zum Zitat Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264:H1998–2006.PubMed Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264:H1998–2006.PubMed
73.
Zurück zum Zitat Perna AF, Smogorzewski M, Massry SG. Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int. 1989;36:453–7.PubMedCrossRef Perna AF, Smogorzewski M, Massry SG. Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int. 1989;36:453–7.PubMedCrossRef
74.
Zurück zum Zitat Rampe D, Lacerda AE, Dage RC, Brown AM. Parathyroid hormone: an endogenous modulator of cardiac calcium channels. Am J Physiol. 1991;261:H1945–50.PubMed Rampe D, Lacerda AE, Dage RC, Brown AM. Parathyroid hormone: an endogenous modulator of cardiac calcium channels. Am J Physiol. 1991;261:H1945–50.PubMed
75.
Zurück zum Zitat Deluca HF, Engstrom GW, Rasmussen H. The action of vitamin D and parathyroid hormone in vitro on calcium uptake and release by kidney mitochondria. Proc Natl Acad Sci U S A. 1962;48:1604–9.PubMedCrossRef Deluca HF, Engstrom GW, Rasmussen H. The action of vitamin D and parathyroid hormone in vitro on calcium uptake and release by kidney mitochondria. Proc Natl Acad Sci U S A. 1962;48:1604–9.PubMedCrossRef
76.
Zurück zum Zitat Sallis JD, Deluca HF, Rasmussen H. Parathyroid hormone-dependent uptake of inorganic phosphate by mitochondria. J Biol Chem. 1963;238:4098–102.PubMed Sallis JD, Deluca HF, Rasmussen H. Parathyroid hormone-dependent uptake of inorganic phosphate by mitochondria. J Biol Chem. 1963;238:4098–102.PubMed
77.
Zurück zum Zitat Sallis JD, DeLuca HF. Action of parathyroid hormone on mitochondria. Magnesium- and phosphate-independent respiration. J Biol Chem. 1966;241:1122–7.PubMed Sallis JD, DeLuca HF. Action of parathyroid hormone on mitochondria. Magnesium- and phosphate-independent respiration. J Biol Chem. 1966;241:1122–7.PubMed
78.
Zurück zum Zitat Kimmich GA, Rasmussen H. The effect of parathyroid hormone on mitochondrial ion transport in the terminal portion of the cytochrome chain. Biochim Biophys Acta. 1966;113:457–66.PubMedCrossRef Kimmich GA, Rasmussen H. The effect of parathyroid hormone on mitochondrial ion transport in the terminal portion of the cytochrome chain. Biochim Biophys Acta. 1966;113:457–66.PubMedCrossRef
79.
Zurück zum Zitat Rasmussen H, Ogata E. Parathyroid hormone and the reactions of mitochondria to cations. Biochemistry. 1966;5:733–45.PubMedCrossRef Rasmussen H, Ogata E. Parathyroid hormone and the reactions of mitochondria to cations. Biochemistry. 1966;5:733–45.PubMedCrossRef
80.
Zurück zum Zitat Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal. 2005;7:1302–14.PubMedCrossRef Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal. 2005;7:1302–14.PubMedCrossRef
81.
Zurück zum Zitat Palty R, Silverman WF, Hershfinkel M, Caporale T, Sensi SL, Parnis J, et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc Natl Acad Sci U S A. 2010;107:436–41.PubMedCrossRef Palty R, Silverman WF, Hershfinkel M, Caporale T, Sensi SL, Parnis J, et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc Natl Acad Sci U S A. 2010;107:436–41.PubMedCrossRef
82.
Zurück zum Zitat Kuo TH, Zhu L, Golden K, Marsh JD, Bhattacharya SK, Liu BF. Altered Ca2+ homeostasis and impaired mitochondrial function in cardiomyopathy. Mol Cell Biochem. 2002;238:119–27.PubMedCrossRef Kuo TH, Zhu L, Golden K, Marsh JD, Bhattacharya SK, Liu BF. Altered Ca2+ homeostasis and impaired mitochondrial function in cardiomyopathy. Mol Cell Biochem. 2002;238:119–27.PubMedCrossRef
83.
Zurück zum Zitat Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevée N. Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol. 2003;85:383–8.PubMedCrossRef Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevée N. Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol. 2003;85:383–8.PubMedCrossRef
84.
Zurück zum Zitat Perrier R, Richard S, Sainte-Marie Y, Rossier BC, Jaisser F, Hummler E, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol. 2005;569:153–62.PubMedCrossRef Perrier R, Richard S, Sainte-Marie Y, Rossier BC, Jaisser F, Hummler E, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol. 2005;569:153–62.PubMedCrossRef
85.
Zurück zum Zitat Schlüter KD, Weber M, Piper HM. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J. 1995;310:439–44.PubMed Schlüter KD, Weber M, Piper HM. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J. 1995;310:439–44.PubMed
86.
Zurück zum Zitat Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34–41.PubMedCrossRef Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34–41.PubMedCrossRef
87.
Zurück zum Zitat Lütteke D, Ross G, Abdallah Y, Schäfer C, Piper HM, Schlüter KD. Parathyroid hormone-related peptide improves contractile responsiveness of adult rat cardiomyocytes with depressed cell function irrespectively of oxidative inhibition. Basic Res Cardiol. 2005;100:320–7.PubMedCrossRef Lütteke D, Ross G, Abdallah Y, Schäfer C, Piper HM, Schlüter KD. Parathyroid hormone-related peptide improves contractile responsiveness of adult rat cardiomyocytes with depressed cell function irrespectively of oxidative inhibition. Basic Res Cardiol. 2005;100:320–7.PubMedCrossRef
88.
Zurück zum Zitat Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schlüter KD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res. 2009;82:77–83.PubMedCrossRef Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schlüter KD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res. 2009;82:77–83.PubMedCrossRef
89.
Zurück zum Zitat Kamalov G, Ahokas RA, Zhao W, Johnson PL, Shahbaz AU, Bhattacharya SK, et al. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol. 2010;298:H385–94.PubMedCrossRef Kamalov G, Ahokas RA, Zhao W, Johnson PL, Shahbaz AU, Bhattacharya SK, et al. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol. 2010;298:H385–94.PubMedCrossRef
90.
Zurück zum Zitat Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci. 2006;332:73–8.PubMedCrossRef Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci. 2006;332:73–8.PubMedCrossRef
91.
Zurück zum Zitat Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286–94.PubMedCrossRef Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286–94.PubMedCrossRef
92.
Zurück zum Zitat Yang F, Nickerson PA. Effect of parathyroidectomy on arterial hypertrophy, vascular lesions, and aortic calcium content in deoxycorticosterone-induced hypertension. Res Exp Med (Berl). 1988;188:289–97.CrossRef Yang F, Nickerson PA. Effect of parathyroidectomy on arterial hypertrophy, vascular lesions, and aortic calcium content in deoxycorticosterone-induced hypertension. Res Exp Med (Berl). 1988;188:289–97.CrossRef
93.
Zurück zum Zitat Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335:105–10.PubMedCrossRef Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335:105–10.PubMedCrossRef
94.
95.
Zurück zum Zitat Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065–82.PubMedCrossRef Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065–82.PubMedCrossRef
96.
Zurück zum Zitat Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470–3.PubMedCrossRef Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470–3.PubMedCrossRef
97.
Zurück zum Zitat Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol. 2002;57:51–5.PubMed Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, Butros R, Wedlund PJ, Fanti P. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol. 2002;57:51–5.PubMed
98.
Zurück zum Zitat Zittermann A, Fischer J, Schleithoff SS, Tenderich G, Fuchs U, Koerfer R. Patients with congestive heart failure and healthy controls differ in vitamin D-associated lifestyle factors. Int J Vitam Nutr Res. 2007;77:280–8.PubMedCrossRef Zittermann A, Fischer J, Schleithoff SS, Tenderich G, Fuchs U, Koerfer R. Patients with congestive heart failure and healthy controls differ in vitamin D-associated lifestyle factors. Int J Vitam Nutr Res. 2007;77:280–8.PubMedCrossRef
99.
Zurück zum Zitat Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10:321–7.PubMedCrossRef Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10:321–7.PubMedCrossRef
100.
Zurück zum Zitat Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41–6.PubMedCrossRef Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41–6.PubMedCrossRef
101.
Zurück zum Zitat Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722–7.PubMedCrossRef Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722–7.PubMedCrossRef
102.
Zurück zum Zitat Zia AA, Komolafe BO, Moten M, Ahokas RA, McGee JE, Rosenberg EW, et al. Supplemental vitamin D and calcium in the management of African-Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011;341:113–8.PubMedCrossRef Zia AA, Komolafe BO, Moten M, Ahokas RA, McGee JE, Rosenberg EW, et al. Supplemental vitamin D and calcium in the management of African-Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011;341:113–8.PubMedCrossRef
103.
Zurück zum Zitat Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Cation dyshomeostasis and cardiomyocyte necrosis. The Fleckenstein hypothesis revisited. Eur Heart J. 2011;32:1846–53.PubMedCrossRef Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Cation dyshomeostasis and cardiomyocyte necrosis. The Fleckenstein hypothesis revisited. Eur Heart J. 2011;32:1846–53.PubMedCrossRef
104.
Zurück zum Zitat Cohen AJ, Roe FJ. Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol. 2000;38:237–53.PubMedCrossRef Cohen AJ, Roe FJ. Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol. 2000;38:237–53.PubMedCrossRef
105.
Zurück zum Zitat Teucher B, Dainty JR, Spinks CA, Majsak-Newman G, Berry DJ, Hoogewerff JA, et al. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res. 2008;23:1477–85.PubMedCrossRef Teucher B, Dainty JR, Spinks CA, Majsak-Newman G, Berry DJ, Hoogewerff JA, et al. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res. 2008;23:1477–85.PubMedCrossRef
106.
Zurück zum Zitat Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35–41.PubMedCrossRef Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35–41.PubMedCrossRef
107.
Zurück zum Zitat Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Bieglmayer C, Pacher R, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant. 2003;22:843–50.PubMedCrossRef Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Bieglmayer C, Pacher R, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant. 2003;22:843–50.PubMedCrossRef
108.
Zurück zum Zitat Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K, et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med. 2003;253:439–46.PubMedCrossRef Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K, et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med. 2003;253:439–46.PubMedCrossRef
109.
Zurück zum Zitat Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int. 2006;17:1420–7.PubMedCrossRef Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int. 2006;17:1420–7.PubMedCrossRef
110.
Zurück zum Zitat Frost RJ, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol. 2007;156:309–14.PubMedCrossRef Frost RJ, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol. 2007;156:309–14.PubMedCrossRef
111.
Zurück zum Zitat Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr. 2009;49:250–4.PubMedCrossRef Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr. 2009;49:250–4.PubMedCrossRef
112.
Zurück zum Zitat van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118:1946–52.PubMedCrossRef van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118:1946–52.PubMedCrossRef
113.
Zurück zum Zitat Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure. Risk reduction with spironolactone. J Am Coll Cardiol. 2008;52:135–8.PubMedCrossRef Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure. Risk reduction with spironolactone. J Am Coll Cardiol. 2008;52:135–8.PubMedCrossRef
114.
Zurück zum Zitat Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46:142–6.PubMedCrossRef Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46:142–6.PubMedCrossRef
115.
Zurück zum Zitat Kamalov G, Deshmukh PA, Baburyan NY, Gandhi MS, Johnson PL, Ahokas RA, et al. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2009;53:414–23.PubMedCrossRef Kamalov G, Deshmukh PA, Baburyan NY, Gandhi MS, Johnson PL, Ahokas RA, et al. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2009;53:414–23.PubMedCrossRef
116.
Zurück zum Zitat Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med. 1998;104:508–9.PubMed Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med. 1998;104:508–9.PubMed
117.
Zurück zum Zitat Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure [German]. Z Kardiol. 1992;81:121–5.PubMed Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure [German]. Z Kardiol. 1992;81:121–5.PubMed
118.
Zurück zum Zitat Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105–12.PubMedCrossRef Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105–12.PubMedCrossRef
119.
Zurück zum Zitat Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395–8.PubMedCrossRef Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395–8.PubMedCrossRef
120.
Zurück zum Zitat Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591–8.PubMedCrossRef Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591–8.PubMedCrossRef
121.
Zurück zum Zitat Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765–71.PubMedCrossRef Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765–71.PubMedCrossRef
122.
Zurück zum Zitat Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186–92.PubMedCrossRef Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186–92.PubMedCrossRef
123.
Zurück zum Zitat Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162:331–9.PubMedCrossRef Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162:331–9.PubMedCrossRef
124.
Zurück zum Zitat Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58:1433–41.PubMedCrossRef Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58:1433–41.PubMedCrossRef
125.
Zurück zum Zitat Loncar G, Bozic B, Dimkovic S, Prodanovic N, Radojicic Z, Cvorovic V, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011;34:e78–85.PubMed Loncar G, Bozic B, Dimkovic S, Prodanovic N, Radojicic Z, Cvorovic V, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011;34:e78–85.PubMed
126.
Zurück zum Zitat Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55:601–6.PubMedCrossRef Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55:601–6.PubMedCrossRef
127.
Zurück zum Zitat Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D–markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13:626–32.PubMedCrossRef Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D–markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13:626–32.PubMedCrossRef
128.
Zurück zum Zitat Carlstedt F, Lind L, Wide L, Lindahl B, Hänni A, Rastad J, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest. 1997;27:977–81.PubMedCrossRef Carlstedt F, Lind L, Wide L, Lindahl B, Hänni A, Rastad J, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest. 1997;27:977–81.PubMedCrossRef
129.
Zurück zum Zitat Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S. Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest. 1998;28:898–903.PubMedCrossRef Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S. Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest. 1998;28:898–903.PubMedCrossRef
130.
Zurück zum Zitat Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691–5.PubMedCrossRef Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691–5.PubMedCrossRef
131.
Zurück zum Zitat Kuwabara Y, Sato Y, Miyamoto T, Taniguchi R, Matsuoka T, Isoda K, et al. Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J. 2007;71:1047–51.PubMedCrossRef Kuwabara Y, Sato Y, Miyamoto T, Taniguchi R, Matsuoka T, Isoda K, et al. Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J. 2007;71:1047–51.PubMedCrossRef
132.
Zurück zum Zitat Peacock 4th WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.PubMedCrossRef Peacock 4th WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.PubMedCrossRef
133.
Zurück zum Zitat Zairis MN, Tsiaousis GZ, Georgilas AT, Makrygiannis SS, Adamopoulou EN, Handanis SM, et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol. 2009;141:284–90.PubMedCrossRef Zairis MN, Tsiaousis GZ, Georgilas AT, Makrygiannis SS, Adamopoulou EN, Handanis SM, et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol. 2009;141:284–90.PubMedCrossRef
134.
Zurück zum Zitat Löwbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest. 2004;64:667–76.PubMedCrossRef Löwbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest. 2004;64:667–76.PubMedCrossRef
135.
Zurück zum Zitat Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–8.PubMedCrossRef Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–8.PubMedCrossRef
136.
Zurück zum Zitat Sukova J, Ostadal P, Widimsky P. Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol. 2007;12:153–6.PubMed Sukova J, Ostadal P, Widimsky P. Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol. 2007;12:153–6.PubMed
137.
Zurück zum Zitat Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772–9.PubMedCrossRef Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772–9.PubMedCrossRef
138.
Zurück zum Zitat Sato Y, Nishi K, Taniguchi R, Miyamoto T, Fukuhara R, Yamane K, et al. In patients with heart failure and non-ischemic heart disease, cardiac troponin T is a reliable predictor of long-term echocardiographic changes and adverse cardiac events. J Cardiol. 2009;54:221–30.PubMedCrossRef Sato Y, Nishi K, Taniguchi R, Miyamoto T, Fukuhara R, Yamane K, et al. In patients with heart failure and non-ischemic heart disease, cardiac troponin T is a reliable predictor of long-term echocardiographic changes and adverse cardiac events. J Cardiol. 2009;54:221–30.PubMedCrossRef
139.
Zurück zum Zitat Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009;54:1715–21.PubMedCrossRef Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009;54:1715–21.PubMedCrossRef
Metadaten
Titel
Parathyroid Hormone, A Crucial Mediator of Pathologic Cardiac Remodeling in Aldosteronism
verfasst von
Michael R. Rutledge
Victor Farah
Adedayo A. Adeboye
Michael R. Seawell
Syamal K. Bhattacharya
Karl T. Weber
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 2/2013
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-012-6378-0

Weitere Artikel der Ausgabe 2/2013

Cardiovascular Drugs and Therapy 2/2013 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.